Compare ALUR & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALUR | BCDA |
|---|---|---|
| Founded | 2009 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.9M | 14.5M |
| IPO Year | N/A | N/A |
| Metric | ALUR | BCDA |
|---|---|---|
| Price | $1.36 | $1.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $9.25 | ★ $25.00 |
| AVG Volume (30 Days) | ★ 111.0K | 67.7K |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $17,208,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.02 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.02 | $1.00 |
| 52 Week High | $16.81 | $3.20 |
| Indicator | ALUR | BCDA |
|---|---|---|
| Relative Strength Index (RSI) | 38.81 | 45.91 |
| Support Level | $1.46 | $1.22 |
| Resistance Level | $1.71 | $1.38 |
| Average True Range (ATR) | 0.13 | 0.10 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 10.16 | 37.50 |
Allurion Technologies Inc is a medical device company that focuses on creating a weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).